3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lung Neoplasms
3
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Gallbladder Neoplasms
1
Castration Resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Camurati-Engelmann Syndrome
1
Breast Neoplasms
1
Interventions
Pemetrexed
10
Cisplatin
9
Gemcitabine
8
Nivolumab
5
Ipilimumab
4
Carboplatin
4
niraparib
3
durvalumab
3
Vinorelbine
3
Bevacizumab
3
tremelimumab
2
pembrolizumab
2
olaparib
2
anetumab ravtansine
2
Radiotherapy, Intensity-Modulated
2
Oxaliplatin
2
Imatinib Mesylate
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fluorodeoxyglucose F18
2
Cytoreduction Surgical Procedures
2
vandetanib
1
tislelizumab
1
tazemetostat
1
spartalizumab
1
sargramostim
1
ribociclib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
defactinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma
×
bintrafusp alfa protein, human
×
Clear all
NCT05005429
2025-12-23
BIMES
Fundación GECP
Phase 2
Completed
47 enrolled
9 charts